Key Points
- Insider sale: Carl Dambkowski sold 5,500 Apogee Therapeutics shares for approximately $737,935 under a pre-arranged Rule 10b5-1 trading plan, reducing his position by 3.16% to 168,498 shares.
- Stock and analyst sentiment: APGE opened at $134.84, near its 12-month high of $134.88. Analysts have a consensus “Hold” rating with a $121.25 price target, despite the stock’s recent gains.
- Business outlook: Apogee is a clinical-stage biotechnology company developing oral therapies targeting inflammatory and autoimmune disorders; its lead candidate, APG-157, is in early-stage testing for moderate to severe plaque psoriasis.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total transaction of $737,935.00. Following the completion of the transaction, the insider directly owned 168,498 shares of the company's stock, valued at $22,607,376.66. The trade was a 3.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, July 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $132.74, for a total transaction of $730,070.00.
- On Monday, June 22nd, Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock. The stock was sold at an average price of $132.60, for a total transaction of $3,500,640.00.
- On Wednesday, June 3rd, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $78.71, for a total transaction of $432,905.00.
Apogee Therapeutics Price Performance
Shares of NASDAQ APGE opened at $134.84 on Friday. The company has a 50-day simple moving average of $119.35 and a 200-day simple moving average of $91.88. The company has a market cap of $8.34 billion, a PE ratio of -31.14 and a beta of 0.34. Apogee Therapeutics Inc. has a 12 month low of $34.34 and a 12 month high of $134.88.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.01. On average, analysts anticipate that Apogee Therapeutics Inc. will post -4.45 EPS for the current year.
Analyst Ratings Changes
APGE has been the subject of several analyst reports. UBS Group downgraded Apogee Therapeutics from a "buy" rating to a "neutral" rating and boosted their price target for the company from $100.00 to $135.11 in a report on Tuesday, June 23rd. Canaccord Genuity Group cut Apogee Therapeutics from a "buy" rating to a "hold" rating and raised their price objective for the stock from $130.00 to $135.11 in a report on Monday, June 22nd. Craig Hallum set a $135.11 price objective on Apogee Therapeutics and gave the company a "hold" rating in a research report on Monday, June 22nd. Guggenheim lowered Apogee Therapeutics from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 23rd. Finally, Rothschild & Co Redburn began coverage on Apogee Therapeutics in a research report on Friday, May 1st. They set a "buy" rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $121.25.
View Our Latest Stock Report on Apogee Therapeutics
Institutional Investors Weigh In On Apogee Therapeutics
Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Apogee Therapeutics by 40.5% during the second quarter. GAMMA Investing LLC now owns 309 shares of the company's stock worth $41,000 after purchasing an additional 89 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Apogee Therapeutics during the 4th quarter valued at $25,000. Los Angeles Capital Management LLC purchased a new stake in shares of Apogee Therapeutics during the 4th quarter valued at $37,000. Longfellow Investment Management Co. LLC acquired a new stake in shares of Apogee Therapeutics during the 2nd quarter worth $81,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Apogee Therapeutics by 61.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company's stock worth $54,000 after buying an additional 246 shares during the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
